Semaglutide Linked to NAION Risk - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Semaglutide Linked to NAION Risk

A retrospective database study found a low absolute incidence but higher relative hazard of ischemic optic neuropathy following semaglutide initiation.

  • By

  • Andrea Surnit

  • May 11, 2026

  • 3 min

Share

  • 1

    Semaglutide use in diabetes patients is linked to a higher long-term risk of nonarteritic anterior ischemic optic neuropathy (NAION).

  • 2

    The study analyzed data from approximately 3.35 million diabetes patients, comparing 174,584 semaglutide users to matched non-GLP-1 RA users.

  • 3

    NAION risk was not significantly increased within the first year of semaglutide treatment but showed elevated risk at 2 and 4 years.

  • 4

    Subgroup analyses indicated higher NAION risk among patients aged 40-64, females, White patients, and those with hypertension.

  • 5

    The study's limitations include its retrospective design, potential outcome misclassification, and inability to establish causality.

Original Source(s)

Semaglutide Linked to NAION Risk

  • by Andrea Surnit

  • May 11, 2026

Related Content

Myopia Severity Tied to Pediatric Retinal Pathology

Routine dilated examinations identified peripheral retinal abnormalities across refractive groups, with higher pathology rates among patients with at least 3.00 D of myopia

Blindness Linked to Higher Loneliness Scores

Analysis of more than 61,000 patients found higher odds of elevated loneliness scores among those reporting blindness and those with diabetic retinopathy, but not among patients with glaucoma or age-related macular degeneration.

Assessment of Two-Phase Diagnostic Timelines in Diabetic Retinopathy and Contributing Factors: A Cross-Sectional Analysis